RTX – Revolutionary Chronic Pain Treatment May Reduce Opioid Reliance

1. RTX – Revolutionary Chronic Pain
Treatment May Reduce Opioid
Reliance
By: Robert Hindes MD

2. RTX – Revolutionary Chronic Pain Treatment May
Reduce Opioid Reliance
The former chief medical officer of Trek Therapeutics, Robert Hindes, MD, has been working with
various drug development companies in Connecticut and New Jersey. Most recently the former
vice president of clinical research at Sorrento Therapeutics, Robert Hindes, MD, was involved in
the development of resiniferatoxin (RTX).

3. RTX – Revolutionary Chronic Pain Treatment May
Reduce Opioid Reliance
RTX is an injectable treatment to help patients with chronic pain in illnesses such as degenerative
arthritis and cancer. The chemical targets nerve endings that transmit pain signals locally and
debilitates them, permanently blocking the pain signal. This has the potential to revolutionize pain
treatment. Here’s why:

4. RTX – Revolutionary Chronic Pain Treatment May
Reduce Opioid Reliance
- RTX targets nerve pathways that transmit pain signals from sources such as tumors and joints.
The chemical does not affect the workings of other nerves. It interacts with nerves without inhibiting
sensations such as pressure and touch.

5. RTX – Revolutionary Chronic Pain Treatment May
Reduce Opioid Reliance
- RTX has none of the undesirable side effects of heavy opioids use. When neurons that transmit
chronic pain signals are overused, such as in patients with cancer, the neurons become especially
sensitive to pain, forcing patients to take larger doses of opioids to manage the pain. RTX
permanently debilitates the nerve pathways, removing dependence on opioids.